Limertinib with radiation for lung cancer that has spread to the brain
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests a new targeted pill (limertinib) combined with radiation therapy for people with a specific type of lung cancer (EGFR-mutant) that has spread to the brain. The goal is to see if this combination can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced non-small cell lung cancer (a common type of lung cancer) that has spread to the brain, with at least 3 brain lesions and one measuring at least 2 cm.
- Your cancer has a specific genetic change called an EGFR mutation (19Del or 21L858R).
- You have not had any prior treatment for advanced or metastatic lung cancer, such as chemotherapy, targeted therapy, or immunotherapy.
- You are in generally good health (able to care for yourself, with a performance status of 0 or 1) and have adequate organ function (blood counts, liver, and kidney).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted pills (furmonertinib and anlotinib) as a first treatment for people with advanced EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to see if this combination works better than the standard approach for controlling the cancer.
This trial tests combining a targeted pill (firmonertinib) with medication injected into the fluid around the spine for people with a specific type of lung cancer that has spread to the lining of the brain. It may offer a new option if you have already tried other EGFR drugs and are still having progression.
This trial tests a targeted pill called repotrectinib for people with a specific type of lung cancer (ROS1-positive non-small cell lung cancer) that has spread to the brain. The drug aims to shrink brain tumors and control the cancer, especially when brain-focused treatments like surgery or radiation are not needed right away.
This trial tests two different treatment plans before lung cancer surgery. Both plans start with a targeted pill (limertinib), then one adds immunotherapy plus chemotherapy, and the other adds just chemotherapy. The goal is to see which combination helps shrink the tumor more before surgery.
This trial tests if adding an injected chemotherapy drug (pemetrexed) to a targeted oral pill (like osimertinib) works better than the pill alone for patients with lung cancer that has spread to the brain and spinal cord lining.
This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.